FY26-27 Pediatric Covid-19 Vaccines

SOL #: 75D30126R73403Combined Synopsis/Solicitation

Overview

Buyer

Health And Human Services

Centers For Disease Control And Prevention

CDC OFFICE OF ACQUISITION SERVICES

ATLANTA, GA, 30333, United States

Place of Performance

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

Drugs And Biologicals (6505)

Set Aside

No set aside specified

Original Source

https://sam.gov/opp/aebabf71e3134473a5503a098c35b260/view

Timeline

Posted

Mar 4, 2026

Last Updated

Mar 4, 2026

Submission Deadline

Mar 17, 2026, 5:00 PM

Qualification Details

Fit reasons

NAICS alignment with historical contract wins in similar service areas.
Scope strongly matches core technical capabilities and delivery model.

Risks

Past performance thresholds may require one additional teaming partner.
Potential clarification needed on staffing minimums before bid/no-bid.

Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Centers for Disease Control and Prevention (CDC) is soliciting proposals for Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts to procure standard commercial adult COVID-19 vaccines for the 2025-2026 and 2026-2027 seasons. This Unrestricted opportunity aims to secure vaccines for distribution to state and local health departments. Proposals are due March 17, 2026, at 1:00 PM EDT.

Opportunity Overview

The CDC intends to award one or more ID/IQ contracts to manufacturers of FDA-approved adult COVID-19 vaccines (age 19 years and older). The primary goal is to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below the commercial marketplace, supporting adult immunization programs. While the opportunity title mentions "Pediatric Covid-19 Vaccines," the detailed solicitation specifies "adult COVID-19 vaccines."

Key Requirements & Deliverables

Product: Standard commercial adult COVID-19 vaccines (age 19+).
Quantity: Minimum order size of 100 doses; maximum of 10 million doses per item.
Shelf Life: Minimum 12 months remaining upon delivery.
Delivery: Within 15 working days after receipt of order to CDC centralized distribution locations (Olive Branch, MS and Clermont, KY) or specified clinic locations.
Compliance: Vaccines must be manufactured under current FDA establishment and product license, adhere to Current Good Manufacturing Practice Regulations (CGMPRs), and comply with DSCSA requirements. Contractors must also interface with the CDC electronic vaccine ordering system (VTrckS).
Attachments: An Authorized Distributor of Record (ADR) Agreement (Attachment 1) and a List of Products (Attachment 2) are integral to this solicitation.

Contract Details

Contract Type: Indefinite Delivery/Indefinite Quantity (ID/IQ) with Firm-Fixed-Price delivery orders.
Period of Performance: Orders may be issued from June 1, 2026, through May 31, 2027. The contract period of performance is 12 months from the date of award.
Maximum Contract Value: Combined maximum value for all contracts is $892,363,500.00.
Pricing: Contract unit prices shall not exceed the manufacturer’s current Federal Ceiling Price (FCP), with Federal Excise Tax ($0.75 per dose) applicable.
NAICS Code: 325412.

Eligibility & Submission

Set-Aside: This is an Unrestricted acquisition.
Offerors: Must be manufacturers of FDA-approved vaccines.
Subcontracting: Subcontracting plans are required for other than small business offerors, to be submitted via the HHS Small Business Customer Experience (SBCX) system.
Proposal Submission: Electronic via email to the specified CDC contacts.
Evaluation Factors: Proposals will be evaluated based on Technical Proposal (meeting vaccine requirements, shelf life, FDA licensure, pricing, VTrckS interface), Price Proposal, and Past Performance.